---
title: "Bank of America Securities Remains a Buy on Denali Therapeutics (DNLI)"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/266041817.md"
description: "Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Denali Therapeutics with a $26 price target. The stock closed at $17.44, suggesting significant upside potential. The analyst consensus is a Strong Buy with a $31 average price target, indicating a 77.75% upside. H.C. Wainwright also reiterated a Buy rating with a $32 target."
datetime: "2025-11-15T17:35:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/266041817.md)
  - [en](https://longbridge.com/en/news/266041817.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/266041817.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/266041817.md) | [English](https://longbridge.com/en/news/266041817.md)


# Bank of America Securities Remains a Buy on Denali Therapeutics (DNLI)

In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Denali Therapeutics, with a price target of $26.00. The company’s shares closed yesterday at $17.44.

### Meet Your ETF AI Analyst

-   Discover how TipRanks' _ETF_ AI Analyst can help you make smarter investment decisions
-   Explore ETFs TipRanks' users love and see what insights the **_ETF_ AI Analyst** reveals about the ones you follow.

Ahmad covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Incyte, and BioNTech SE. According to TipRanks, Ahmad has an average return of 1.8% and a 54.71% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Denali Therapeutics with a $31.00 average price target, implying a 77.75% upside from current levels. In a report released on November 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $32.00 price target.

### 相關股票

- [Denali Therap (DNLI.US)](https://longbridge.com/zh-HK/quote/DNLI.US.md)

## 相關資訊與研究

- [Denali Regains DNL593 Rights After Takeda Collaboration Ends](https://longbridge.com/zh-HK/news/281657527.md)
- [Denali Therapeutics Secures $200 Million Royalty Funding](https://longbridge.com/zh-HK/news/281213273.md)
- [DENARIUS METALS FILES 2025 ANNUAL FILINGS ON SEDAR+ | DNRSF Stock News](https://longbridge.com/zh-HK/news/281291504.md)
- [Trump Has No Good Options: UNSW's Genauer](https://longbridge.com/zh-HK/news/281330773.md)
- [VegaShares Launches the First Multi-Index Covered Call Income ETF (ODTE) | ODTE Stock News](https://longbridge.com/zh-HK/news/281553894.md)